Document is current
Any future updates will be listed below
-
Authors
Ceder, Sophia https://orcid.org/0000-0002-6195-9288
Eriksson, Sofi E https://orcid.org/0000-0001-5214-9219
Cheteh, Emarndeena H https://orcid.org/0000-0002-9216-6942
Dawar, Swati https://orcid.org/0000-0001-5194-9193
Corrales Benitez, Mariana
Bykov, Vladimir J N https://orcid.org/0000-0002-7199-8942
Fujihara, Kenji M https://orcid.org/0000-0002-8387-4912
Grandin, Mélodie https://orcid.org/0000-0001-6784-9496
Li, Xiaodun https://orcid.org/0000-0002-5859-9429
Ramm, Susanne https://orcid.org/0000-0003-1108-5620
Behrenbruch, Corina
Simpson, Kaylene J https://orcid.org/0000-0001-9136-1781
Hollande, Frédéric https://orcid.org/0000-0002-7046-8392
Abrahmsen, Lars
Clemons, Nicholas J https://orcid.org/0000-0001-9283-9978
Wiman, Klas G https://orcid.org/0000-0002-7113-524X
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2017‐01509)
Cancerfonden (18 0774)
Barncancerfonden (PR2017‐0106)
Radiumhemmets Forskningsfonder (171213)
Knut och Alice Wallenbergs Stiftelse
Aprea Therapeutics
Karolinska Institutet
Department of Health, Australian Government | National Health and Medical Research Council (APP1120293)
Department of Health, Australian Government | National Health and Medical Research Council (GNT1164081)
Department of Health and Human Services, State Government of Victoria (MCRF16002)
Tour de Cure Foundation (RSP ‐ 0004 ‐ 17/18)
UKRI | Medical Research Council (RG84369)
Australian Cancer Research Foundation
Australian Government’s National Collaborative Research Infrastructure Strategy (NCRIS) program
Peter MacCallum Cancer Centre Foundation
University of Melbourne Research Collaborative Infrastructure Program
Cancer Research UK (RG81771/84119)
- License Information
-
More Information
Article History
Received: 7 May 2019
Revised: 16 November 2020
Accepted: 17 November 2020
First Online: 14 December 2020
Conflict of interest
: This study was funded in part by Aprea Therapeutics, a company that develops p53‐based cancer therapy, including APR‐246. K.G.W. and V.J.N.B. are co‐founders and shareholders of Aprea Therapeutics. K.G.W. is also a member of its Clinical Advisory Board. K.G.W. and V.J.N.B. have received a salary from Aprea Therapeutics. L.A. is Chief Scientific Officer of Aprea Therapeutics.
